登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>OX40 >CHEK-ATP053

HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line

For research use only.

描述(Description)

HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line

应用说明(Application)

Binding assay by FACS and cell based ELISA

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puromycin (5 μg/mL)

培养基(Culture Medium)

DMEM medium + 10% FBS

冻存液(Freeze Medium)

10% DMSO + 90% FBS

装量(Quantity)

1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

活性(Bioactivity)

OX40 FACS

FACS assay shows that Biotinylated Human OX40 Ligand, Avitag,Fc Tag (OXL-H82F4) can bind to HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line(HEK-ATP053). HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).

Protocol

 

背景(Background)

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

 

License Disclosure

This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
OX40靶点信息
英文全称:Tumor necrosis factor receptor superfamily member 4
中文全称:肿瘤坏死因子受体超家族成员4
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:27详情
最高研发阶段:临床三期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定